Clinical Pharmacology of Chemotherapy Agents in Older People with Cancer
Open Access
- 10 August 2011
- journal article
- review article
- Published by Hindawi Limited in Current Gerontology and Geriatrics Research
- Vol. 2011, 1-6
Abstract
Populations around the world are aging, and the associated increase in cancer incidence has led to the recognition of the importance of geriatric oncology. Chronological age is a poor determinant of pharmacological response to cancer chemotherapy agents. Age-associated changes in physiology and organ function have a significant impact on the clinical pharmacology of cancer chemotherapy agents used in cancer treatment. Altered response to medicines in older people is a consequence of changes in body composition, organ function, concomitant pathophysiology, multiple medications, genetic determinants of drug response, and patient's clinical status. These issues highlight the need to individualize the management of cancer in the older people with consideration of age-related changes in the clinical pharmacology of cancer drugs, analgesics, and adjunctive therapies.Keywords
This publication has 52 references indexed in Scilit:
- Regulation of Drug-Metabolizing Enzymes and Transporters in Infection, Inflammation, and CancerDrug Metabolism and Disposition, 2008
- Clinical pharmacology in the geriatric patientFundamental & Clinical Pharmacology, 2007
- Research Agenda for Frailty in Older Adults: Toward a Better Understanding of Physiology and Etiology: Summary from the American Geriatrics Society/National Institute on Aging Research Conference on Frailty in Older AdultsJournal of the American Geriatrics Society, 2006
- Regulation of drug metabolism and disposition during inflammation and infectionExpert Opinion on Drug Metabolism & Toxicology, 2005
- Aging Biology and Geriatric Clinical PharmacologyPharmacological Reviews, 2004
- Prognostic Importance of Comorbidity in a Hospital-Based Cancer RegistryJAMA, 2004
- Fluid and Electrolytes in the AgedArchives of Surgery, 2003
- Inflammatory response: an unrecognised source of variability in the pharmacokinetics and pharmacodynamics of cancer chemotherapyThe Lancet Oncology, 2003
- Transitions in Health Care Use and Expenditures Among Frail Older Adults by Payor/Provider TypeJournal of the American Geriatrics Society, 1997
- Influence of Diet and Nutritional Status on Drug MetabolismClinical Pharmacokinetics, 1996